DAFTAR PUSTAKA
1. Hossain P, Kawar B, El Nahas M. Obesity and Diabetes in developing world: a growing Chalengge. In : N Engl J Med. 2007; 356:213-15. 2. Sugondo S. Obesitas. Dalam : Buku Ajar Ilmu Penyakit Dalam. Sudoyo
AW, Setiyohadi B, Alwi I, dkk (Eds). Jakarta. Pusat Penerbitan Ilmu Penyakit Dalam FKUI 2009; 5:3:1973-83.
3. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flagel KM. Prevalence of overweight and obesity in the United Stated, 1999-2004. JAMA. 2006; 295:1549-55.
4. Savage DB, Petersen KF, Shulman GI, Disordered Lipid Metabolism and the Pathogenesis of Insulin Resistance, 2007; 87: 507-20.
5. Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Haring HU, et al, Fetuin-A Induce Cytokine Expression and Suppresses Adiponectin Production. Plos ONE, 2008; 3:3:1-9.
6. Reinehr T, Roth CL. Fetuin-A and Its Relation to Metabolic Syndrome and Fatty Liver Disease in Obese Children Before and After Weight loss : The Journal of Clinical Endocrinology Metabolism 2008; 93:4479-85. 7. Joachim HI, Michael G, Shlipak, Vincent M, Bradenburg, Sadia A, et al,
Association Between Human Fetuin-A and the Metabolic Syndrome :Data from American Heart Association. 2006;113:1760-67.
8. Molitch ME, Fujimoto W, Hammon RF, Knowler WC. The diabetes prevention program and its global implications. In: J Am Soc Nephrol; 2003;14:103-7.
9. Ulf G. Bronas, Diane Treat-Jacobson Patricia Painter, Alternative Forms of Exercise Training Complementary Therapy in the Prevention and Management of Type 2 Diabetes. Diabetes Spectrum September 21, 2009; 22:4: 220-225.
11.Diabetes Prevention Program Research Group, Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin, The New England Jounal of Medicine, 2002; 346:6: 393-403.
12.Bray. Medical Consequence of Obesity. In: J Clin Endocrinol Metab; 2004; 89:6: 2583-9.
13.Cavil N, Ells L, Treating adult obesity through lifestyle change interventions. A briefing paper for commissioners. Oxford: National obesity Observatory; 2010; 1-18.
14.Sugondo S. Obesitas pada Sindroma Metabolik : Penyebab atau akibat. Dalam : Naskah lengkap PIT Penyakit Dalam 2005. Jakarta. Pusat Penerbitan Ilmu Penyakit Dalam FKUI. 2005; 83-6.
15.World Health Organization. Redefining obesity and its treatment: The asia pacific perspective, 2013.
16.World Health Organization. Obesity Technical Report Series 894, Geneva. 2000.
17.The National Institute of Health. Clinical Guideline on identification, evaluation and the treatment of overweight and obesity in adult.Obes.Res 2000; 00:4084-9.
18.Stefan N, Haring HU, The Metabolically Benign and Malignant Fatty Liver, 2011; 60:8: 1-6.
19.Kaushik S, Ser312 Fetuin-A Phosphorilation and Its Association with Serum Lipids in Metabolic Syndrom, 2008; 1-116.
20.Papizan JB, Phosphorylation of Fetuin-A Physiological Inhibitor of Insulin Action, Regulated by Insulin and Leptin, 2007; 1-85
21.Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Krober SM, et al: Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 2006; 29: 853-857
22.Bhattacharya S, Kundu R, Bhattacharya SU, Mechanism of Lipid Insulin Resistance: An Overview, Endocrine Metab 2012;27:1: 12-19.
24.Poirier P, Thomas DG, Bray GA, Hong Y, Stern JS, Xavier F, et al, Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss, 2006; 113: 969-76.
25.Brook RD.Obesity, weight loss and vascular function. In: Endocrine;2006;29:21-25.
26.Diabetes Prevention Programs Research Group. Reductioan Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. NEJM;2002; 346:6: 393-403
27.Herman WH, Hoerger T, Brandle M, Hicks K, Sorensen S, Zhang P, The Cost-Effectivenes of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance, 2005; 142:5; 323-332.
28.Ramachandran A, Shenelata C, Mary S, Mukesh B, Bhaskar VJ, Vijay V et al. The Indian Diabetes Prevention Programme Shows that Lifestyle Modification and Metformin Prevent Type 2 Diabetes in Asian Indian Subjects with Impaired Glucose Tolerance (IDPP-1). Diabetologia; 2006;49: 289-297.
29.Ulf G. Bronas, Diane Treat-Jacobson Patricia Painter, Alternative Forms of Exercise Training Complementary Therapy in the Prevention and Management of Type 2 Diabetes. Diabetes Spectrum September 21, 2009; 22:4: 220-225
30.WHO WPR/IASO/IOTF. Redefining Obesity and its treatment. The Asia – Pasific Perspective. 2000.
31.Bray GA. Drugs Used Clinically to Reduce Body Weight In: Clinical Obesity in Adult and Children. Kopelmen PG et al (eds). Balackwell Publishing. 2010;3: 327-338
32.Dahlan S. Besar Sampel dalam Penelitian Kedokteran dan Kesehatan.Jakarta.PT Arkans; 2005; 2: 59.
34.PERKENI. Konsensus Pengelolaan Diabetes Melitus Tipe 2 di Indonesia; Jakarta; 2006
35.Markus A. Neurobiology of obesity. Nat Neurosci. 2005; 8:5: 551-12 36.Vincent HK, Taylor AS, Biomarkers and potential mechanisms of
obesity-induced oxidant stress in human, International Journal of Obesity; 2006; 30: 400-18.
37.Ismail NA, Ragab S, Dayem SA, Elbaky AA, Salah N, Hamed M, et al, Fetuin-A level in obesity: differences in relation to metabolic syndrome and corellation with clinical and laboratory variable, Arch Med Sci, 2012; 8:5: 826-33.
38.Syahbuddin S. Resistensi insulin dan implikasinya. Naskah lengkap forum diabetes nasional 4 Padang. 2007; 1-11
39.Donelly JE, Jacobsen DJ, Heelen KS, Seip R, Smith S. The effect of 18 months intermitten vs continue exercise on aerobic capacity, Body weight and composition. Int Obese; 2000; 24: 566-572.
40.Manaf A. Effect of metformin therapy on plasma adiponectine in obesity with prediabetes patients. Laporan penelitian. 2008
41.Lindarto D. Pengaruh gaya hidup medik tanpa metformin (PHMTM) dan pengaruh gaya hidup medik dengan metformin (PHMM) terhadap parameter chemerin, adiponektin, ADMA, hsCRP dan insulin pada sindroma metabolik (disertasi). Medan: Universitas Sumatera Utara. 2011 42.Abubakar A, Mabrouk MA, Gerie AB, Dikko AA, Aliyu S, Yusuf T et al.
Relation of body mass index with lipid profile and blood pressure in healthy female of lower economy group, in Kaduna norther Nigeria. Asian Journal of Medical Sciences; 2009;1: 94-96
43.Decroli E. Adiponektin: Penatalaksanaan hipertensi pada diabetes. Naskah lengkap pertemuan ilmiah berkala IX Ilmu Penyaki Dalam Padang,2008: 81-89
45.Chan WB. Management of obesity from lifestyle modification to weight reduction surgery. The Hongkong Medical Buletin;2010;15: 5-7
46.Tina L, Dumbar JA, Chapman A, et al. Prevention of type 2 diabetes by lifestyle intervension in an australia primary health care setting: Greather green triangle. BMC; 2007;7-249
47.Ishibashi A, Ikeda Y, Ohguro T, Kumon Y, Yamanaka S, Takata H, et al, Serum fetuin-A is an Independent Markers of Insulin resisten in Japanese Men, J Atheroscler Thromb, 2010; 17:8:925-33. .
48. Brix JM, Stingl H, Holleri F, Schernthaner GH, Kopp HP, Schnernthaner G, Elevated Fetuin-A Consentration in Morbid Obesity Decrease after Dramatic Weight Loss, J Clinical Endocrinol Metab 2010; 95:4877-81. 49. Halomoan BS, Pengaruh Pola Hidup Medis dengan atau tanpa Metformin
terhadap kadar Adiponektin pada penderita Obesitas, 2010.
50.Mannuci E, Ognibene A, Cremasco F, Bardni G, Mencucci A, Pierazzuoli E et al. Effect of metformin on glucogen like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care;2001; 24:489-494 51.Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM. Effects of
initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes. JAMA;2009; 302:1186-1194
